NEW
YORK, June 2, 2023 /PRNewswire/ -- PAVmed
Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a
diversified commercial-stage medical technology company, operating
in the medical device, diagnostics, and digital health sectors, and
its majority-owned digital health subsidiary Veris Health Inc.
("Veris"), today announced its participation as a founding member
of CancerX – a public-private partnership co-hosted by Moffitt
Cancer Center and the Digital Medicine Society ("DiMe"), alongside
the Office for the National Coordinator for Health Information
Technology ("ONC") and Office of the Assistant Secretary for Health
("OASH"). President Biden and Dr. Jill
Biden announced CancerX in February
2023 as part of The White House's national Cancer Moonshot
initiative to serve as a national accelerator to boost innovation
in the fight against cancer.
"We are truly honored to be a founding member of CancerX and
eager to contribute to this important partnership," said
James Mitchell, MD, Veris' Chief
Medical Officer, and board-certified radiation oncologist. "At
Veris, we firmly believe that digital innovations, such as our
Veris Cancer Care Platform, can revolutionize the fight against
cancer and lower the burden and disparities for patients undergoing
cancer care. Together, we have an unprecedented opportunity to
advance best practices in digital health that can positively
influence every step of a cancer patient's journey. We look forward
to collaborating with other CancerX members to help realize the
Cancer Moonshot's ambitious goals."
Veris and other founding members are tasked with driving the
success of CancerX by establishing priorities and practices that
will harness the full power of innovation to achieve the goals of
the Cancer Moonshot initiative. The partnership unites the
diverse stakeholders and innovators necessary to leverage the power
of digital innovation to realize a cancer-free future.
"Multi-stakeholder collaboration is critical to harness the
potential of digital innovation in the fight against cancer, and
we're honored to partner with Veris Health to achieve the ambitious
goals of CancerX," said Smit Patel,
Associate Program Director at DiMe. "Through this impressive
collaboration, we will establish best practices, build capacity,
and demonstrate the impact of innovation on the life of every
person on a cancer journey."
At the end of March 2023, CancerX
announced its inaugural project, "Advancing Digital Innovation to
Improve Equity and Reduce Financial Toxicity in Cancer Care and
Research," to assess, quantify, and enhance the impact of digital
solutions on cancer care cost, access, and outcomes dimensions.
"Beating cancer demands bold innovation and deliberate
collaboration," added Santosh Mohan,
Vice President, Digital, Moffitt Cancer Center. "CancerX is
creating a dynamic ecosystem where ideas can flourish, expertise
and resources can be shared, and innovative solutions can be
rapidly developed and equitably deployed in the fight against
cancer. As a co-host, we take immense pride in the diverse and
inclusive community of pioneers coming together as members, all
driven by a shared commitment to advancing the goals of the Cancer
Moonshot. Together, we will advance the frontiers of cancer
research and treatment through digital innovation, while striving
to reduce the incidence and burden of cancer for all people."
Sign up to receive information on this news and other CancerX
work.
Visit Veris Health for more information about its mission to
enhance cancer treatment through digitally enabled virtual
care.
About PAVmed and Veris Health
PAVmed Inc. is a diversified commercial-stage medical technology
company operating in the medical device, diagnostics, and digital
health sectors. Its majority-owned subsidiary, Veris Health Inc.,
is a digital health company focused on enhanced personalized cancer
care through a comprehensive digital oncology technology platform.
The company is concurrently developing an implantable physiological
monitor, designed to be implanted alongside a vascular access port,
which will interface with the Veris Cancer Care Platform. The
implantable monitor will further enhance the clinical and
commercial value of the platform by providing remote physiologic
data independent of patient compliance. With the incidence of
cancer growing and patients living longer with cancer, the
addressable market opportunity for Veris' products is substantial.
Importantly, commercial success is not predicated on securing
third-party reimbursement, only on sales and product development
execution.
For more information about Veris Health, please visit
www.verishealth.com and for more information about its parent
company PAVmed, please visit www.pavmed.com.
PAVmed's other majority-owned subsidiary, Lucid Diagnostics Inc.
(Nasdaq: LUCD), is a commercial-stage cancer prevention medical
diagnostics company that markets the
EsoGuard® Esophageal DNA Test and
EsoCheck® Esophageal Cell Collection Device—the
first and only commercial tools for widespread early detection of
esophageal precancer to prevent esophageal cancer deaths.
For more information about Lucid Diagnostics, please visit
www.luciddx.com.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risk and uncertainties. Forward-looking statements are any
statements that are not historical facts. Such forward-looking
statements, which are based upon the current beliefs and
expectations of PAVmed's management, are subject to risks and
uncertainties, which could cause actual results to differ from the
forward-looking statements. Risks and uncertainties that may cause
such differences include, among other things, volatility in the
price of PAVmed's common stock; general economic and market
conditions; the uncertainties inherent in research and development,
including the cost and time required to advance PAVmed's products
to regulatory submission; whether regulatory authorities will be
satisfied with the design of and results from PAVmed's clinical and
preclinical studies; whether and when PAVmed's products are cleared
by regulatory authorities; market acceptance of PAVmed's products
once cleared and commercialized; PAVmed's ability to raise
additional funding as needed; and other competitive developments.
In addition, PAVmed has been monitoring the COVID-19 pandemic and
the pandemic's impact on PAVmed's businesses. PAVmed expects the
significance of the COVID-19 pandemic, including the extent of its
effect on its financial and operational results, to be dictated by,
among other things, the success of efforts to contain the pandemic
and the impact of such efforts on PAVmed's businesses. These
factors are difficult or impossible to predict accurately and many
of them are beyond PAVmed's control. In addition, new risks and
uncertainties may arise from time to time and are difficult to
predict. For a further list and description of these and other
important risks and uncertainties that may affect PAVmed's future
operations, see Part I, Item 1A, "Risk Factors," in PAVmed's most
recent Annual Report on Form 10-K filed with the Securities and
Exchange Commission, as the same may be updated in Part II, Item
1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by
PAVmed after its most recent Annual Report. PAVmed disclaims any
intention or obligation to publicly update or revise any
forward-looking statement to reflect any change in its expectations
or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that
actual results will differ from those contained in the
forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pavmed-digital-health-subsidiary-veris-health-joins-cancer-moonshots-cancerx-partnership-as-founding-member-301841148.html
SOURCE PAVmed Inc.